Investors

about us

Recent News
AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF
Sep 22, 2020

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...

Aug 7, 2020

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...

Jul 8, 2020

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™...

Events
Wednesday, March 9, 2016
11:20am - 11:50am EST
Monday, January 11, 2016
5:30pm - 6:00pm EST